The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives.
Payer Insights: Hepatitis C, based on in-depth interviews with 12 leading healthcare payers in the US, is packed with hard-hitting, candid opinions and advice on how, from their perspective, Pharma can get it right in the future.
Gilead’s commercial success with its ground breaking HCV treatment Solvadi has been matched by the opposition of healthcare payers at the cost.
This report gives insights into what US healthcare payers really think about HCV drug pricing, the growing and frighteningly undefined patient population, limited clinical/outcomes data, poor patient adherence and education - and how can industry positively help and respond.
Get Answers to Key Questions
Features of the report
“Someone needs to look at real world data and state what's really working, what's the most cost-effective treatment, because even for genotype 3 patients, peginterferon and ribavirin are still preferred versus adding Sovaldi, but that hasn't come across [and] everybody's just automatically adding it. You're looking at going from ,000 with a 48 week course to 2,000, 3,000 for a 12 week course. So it's really hard to justify some of this.”
“What's changed is not solely a function of hepatitis C. It's been influenced by specialty drugs as a whole, and the realisation that if plans didn't have a specialty tier on their drug benefit, they now should. Sovaldi, snuck up on everybody with its pricing… everybody was thinking of Sovaldi as being just a follow on to Incivek and Victrelis. While they were not inexpensive either, Sovaldi took it to another level. Most plans have put in place prior authorisation criteria that allow for its use.”
“There's a lot of scepticism [and] disbelief or distrust with Gilead and whoever's going to come out next, depending upon what their launch looks like and what their cost is. There's a lot of frustration with the Federal Government in allowing things like this to happen. So I think the next six months are going to be really difficult for the manufacturers. If they come in 20 percent less than what Gilead did and the product is all oral or has a better safety profile, better adherence, better efficacy, I think that they will definitely easily take the market over.”
Table of Contents
for Payer Insights: Hepatitis C [Published by FirstWord Pharma]
|Title||Date Published||Price from||More Details|
| Cancer Immunotherapy: Payer Insight|
IntroductionImmunotherapies are some of the most promising new weapons in the fight against cancer. ...
|01 Oct 2015 by FirstWord Pharma||USD $6,715 (normally
| Biosimilars: US Payer Perspectives|
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
|01 Apr 2015 by FirstWord Pharma||USD $1,866 (normally
| Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives|
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
|01 Apr 2015 by FirstWord Pharma||USD $591 (normally
| Payer Perspectives on Risk Sharing Deals|
IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
|01 Mar 2015 by FirstWord Pharma||USD $591 (normally
| Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?|
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
|25 Feb 2015 by FirstWord Pharma||USD $591 (normally
| Biosimilars: European Payer Perspectives|
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
|06 Jan 2015 by FirstWord Pharma||USD $1,866 (normally
| Orphan Drug Market Access: Payer Insights on the Present and Future|
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
|14 Oct 2014 by FirstWord Pharma||USD $591 (normally
| Patient Assistance Programs: Payer and Pharma Perspectives|
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
|02 Oct 2014 by FirstWord Pharma||USD $591 (normally
| Oncology Market Access Europe – Payer and Industry Perspectives|
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
|03 Jul 2014 by FirstWord Pharma||USD $846 (normally
| Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)|
IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
|01 Nov 2013 by FirstWord Pharma||USD $591 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.